KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Deffered Revenue (2019 - 2022)

Historic Non-Current Deffered Revenue for Esperion Therapeutics (ESPR) over the last 3 years, with Q2 2022 value amounting to $211000.0.

  • Esperion Therapeutics' Non-Current Deffered Revenue fell 8003.78% to $211000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $211000.0, marking a year-over-year decrease of 8003.78%. This contributed to the annual value of $634000.0 for FY2021, which is N/A changed from last year.
  • Per Esperion Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $211000.0 for Q2 2022, which was down 8003.78% from $422000.0 recorded in Q1 2022.
  • Esperion Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $1.1 million during Q2 2021, with a 5-year trough of $211000.0 in Q2 2022.
  • Its 3-year average for Non-Current Deffered Revenue is $637333.3, with a median of $644500.0 in 2019.
  • Within the past 5 years, the most significant YoY rise in Esperion Therapeutics' Non-Current Deffered Revenue was 8003.78% (2022), while the steepest drop was 8003.78% (2022).
  • Quarter analysis of 3 years shows Esperion Therapeutics' Non-Current Deffered Revenue stood at $655000.0 in 2019, then fell by 3.21% to $634000.0 in 2021, then tumbled by 66.72% to $211000.0 in 2022.
  • Its Non-Current Deffered Revenue was $211000.0 in Q2 2022, compared to $422000.0 in Q1 2022 and $634000.0 in Q4 2021.